Janux Therapeutics Inc header image

Janux Therapeutics Inc

JANX

Equity

ISIN null / Valor 111742522

NASDAQ (2026-01-30)

USD 13.71-0.87%

Janux Therapeutics Inc
UMushroom community rating:

3.57 37 votes No rating yet

NegativeNeutralPositive

About company

Janux Therapeutics Inc., founded in 2017, is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary technology to create next-generation T cell engagers designed to target and eliminate cancer cells while minimizing damage to healthy tissues. Janux successfully completed its initial public offering (IPO) in June 2021 and advanced its first therapeutic program to clinical trials in the latter half of 2022. The company's approach emphasizes a collaborative and data-driven culture to foster scientific innovation and accelerate the development of its therapeutic pipeline.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-69.4%1Y

-37.9%3Y

%5Y

Performance

99.8%1Y

112%3Y

103%5Y

Volatility

825 M

Market cap (USD)

1,087,945

Daily traded volume (Shares)

53.71 / 52.27

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.57

37 votes

Performance:

3.57

Innovation:

3.73

Society:

3.51

Nature:

3.41

Robert Higley

United Kingdom, 09 Nov 2025

very therapeutic

Pinjia Li

United Kingdom, 08 Nov 2025

g

Meruert Daniyarkyzy

United Kingdom, 07 Nov 2025

High risk early-stage biotech, potential upside is large, but future growth are uncertain.

EQUITIES OF THE SAME SECTOR

Attendo AB

Attendo AB Valor: 30491576

Annual Return

-50%0%+50%

Risk level

110

-0.89%SEK 88.90

medmix Ltd

medmix Ltd Valor: 112967710

Annual Return

-50%0%+50%

Risk level

110

0.70%CHF 11.46

Xlife Sciences Ltd.

Xlife Sciences Ltd. Valor: 46192960

Annual Return

-50%0%+50%

Risk level

110

4.07%CHF 23.00

Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A. Valor: 2791431

Annual Return

-50%0%+50%

Risk level

110

-1.12%CHF 19.48

Embla Medical hf

Embla Medical hf Valor: 1060135

Annual Return

-50%0%+50%

Risk level

110

0.32%DKK 31.70

H. Lundbeck A/S

H. Lundbeck A/S Valor: 119252584

Annual Return

-50%0%+50%

Risk level

110

1.38%DKK 36.85

EssilorLuxottica SA

EssilorLuxottica SA Valor: 497537

Annual Return

-50%0%+50%

Risk level

110

1.30%EUR 257.90

bioMerieux SA

bioMerieux SA Valor: 38147803

Annual Return

-50%0%+50%

Risk level

110

0.05%EUR 97.80

Ramsay Generale de Sante SA

Ramsay Generale de Sante SA Valor: 1247709

Annual Return

-50%0%+50%

Risk level

110

-1.47%EUR 10.05

Orion Oyj

Orion Oyj Valor: 2553360

Annual Return

-50%0%+50%

Risk level

110

-1.00%EUR 69.20

SIX

FactSet

Clearbit

Logos provided by Clearbit